1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Virtual Advisory Committees Are Coming: US FDA Panels Will Be Smaller, More Focused

 
• By Kate Rawson

Planning for virtual advisory committees is underway; any applications with upcoming PDUFA deadlines with meetings still on the calendar are prime candidates, OND Director Peter Stein says.

FDA Advisory Committee Feature image

The US Food & Drug Administration is moving ahead with plans to host virtual advisory committee meetings as the agency continues to respond to the need for social distancing during the COVID-19 crisis, Office of New Drug Director Peter Stein said in an interview with the Pink Sheet.

The decision to move ahead with virtual advisory committees will build on FDA’s increasing experience with online hosting of large internal meetings – such as the Center for Drug Evaluation & Research’s Medical Policy Council – and after discussion with division directors and FDA’s advisory committee staff on the need and practicalities associated with such an endeavor

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 
• By Bridget Silverman

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.

More from Regulatory Trackers